Stockscreener 앱 받기
28.09
14.20%
-4.65
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Hims & Hers Health Stock (HIMS) Opinions on FDA Peptide Decisions - Quiver Quantitative
Why Is HIMS Stock Rallying 13% Today? - Stocktwits
A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month - Yahoo Finance
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight - Yahoo Finance
Hims & Hers Health (HIMS) Shares Fall After FDA Panel's Negative Vote on Emideltide - GuruFocus
HIMS Maintains by Truist Securities -- Price Target Raised to $2 - GuruFocus
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - Yahoo Finance
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder - Barchart.com
Hims & Hers (HIMS) Stock Looks Cheap On Cash Flow But Pricey After A 313% Run - Yahoo Finance
HIMS Stock Dives Sharply as Uninsured Patients Raise Concerns while FDA Process Remains Uncertain - FXLeaders
HIMS Stock Falls Over 10% Amid Market Fluctuations - GuruFocus
Hims & Hers down as FDA advisors snub first peptide (HIMS:NYSE) - Seeking Alpha
Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock? - TipRanks
Hims & Hers Health Slides as Traders Fade Peptide Rally - Quiver Quantitative
Hims & Hers: Peptide Ruling A Positive, Operational Good Sense Makes 'Buy' Case (Upgrade) - Seeking Alpha
HIMS Stock Climbs Overnight As FDA Advisory Panel Backs 4 Peptides — ‘Pharma Bro’ Martin Shkreli Goes Short - Stocktwits
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance
Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable - TechStock²
Hims & Hers Health: Favorable Decision on Peptides Lifts Investor Appetite but Uncertainty Very High - Morningstar
Telehealth firms urge FDA to legalize peptides, with guardrails - Crain's New York
What Shapes Hims & Hers Health (NYSE:HIMS) Russell 2000 View? - Kalkine Media
FDA Peptide Shift And Leadership Change Could Be A Game Changer For Hims & Hers Health (HIMS) - simplywall.st
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.4% R - GuruFocus
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $30.38, Implies 4% Downside - TradingView
Hims & Hers Health (HIMS) Gains On FDA Panel News, Is The Valuation Gap Still Wide? - Yahoo Finance
HIMS Maintained by Citigroup -- Price Target Raised to $35.00 - GuruFocus
Hims & Hers Stock: What FDA Peptide Decision Means for Telehealth Strategy - Barron's
Hims & Hers Stock Jumps 13% After FDA Panel Backs BPC-157 for Compounding - finance.biggo.com
Hims & Hers Health, Inc. stock Analysis: FDA Catalyst Impacts Neutral Regime - The Cryptonomist
FDA advisers back first of seven peptides under review for looser rules - Reuters
Hims & Hers Health (NYSE:HIMS) rises as FDA BPC-157 decision turns market attention to revenue per subscriber - TechStock²
HIMS Shares Surge Over 10% Following FDA Panel Decision - GuruFocus
HIMS Stock Surges Following FDA Advisory Panel Decision - GuruFocus
Hims & Hers gains as FDA panel endorses peptide BPC-157 (HIMS) - Seeking Alpha
Hims & Hers Health shares jump on FDA’s push to expand BPC-157 access - Investing.com Canada
Hims & Hers stock jumps after FDA panel backs BPC-157 access - Investing.com Canada
Hims & Hers stands to gain if the FDA loosens restrictions on peptides - Reuters
Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails - Bloomberg.com
$Hims & Hers Health (HIMS.US)$ - Moomoo
Hims & Hers Health Inc (HIMS) Shares Fall 3.2% -- What GF Score of 83 Tells Investors - GuruFocus
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI Push - Stocktwits
The FDA Is About to Weigh in on the Great Peptide Debate - inc.com
Form 144 Hims & Hers Health For: 22 July By Investing.com - Investing.com Canada
Hims & Hers Health, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
HIMS Sees Surge in App Downloads Amid Peptide Opportunity - GuruFocus
HIMS Stock Snaps 3-Day Losing Streak: FDA Adds 8 New Peptide Voters Deemed ‘More Qualified And Less Conflicted’ - Stocktwits
$Hims & Hers Health (HIMS.US)$ 24th July is the key peptide hearing? - Moomoo
Lobbying Update: $290,000 of HIMS & HERS HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Hims & Hers stock analysis: growth story meets credibility crisis ahead of FDA catalyst - Investing.com Canada
Hims & Hers Health Stock Short Interest Falls to 31.82% - Quiver Quantitative
HIMS Stock On A 3-Day Slide: CFO Cashes Out $229K In Shares Ahead Of FDA Peptide Meeting - Yahoo Finance
Hims & Hers Chief Accounting Officer Irene Becklund to Depart After Seven Years - citybiz
Technical Reactions to HIMS Trends in Macro Strategies - Stock Traders Daily
HIMS Announces Departure of Chief Accounting Officer Irene Beckl - GuruFocus
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company - 01net
Hims & Hers Health Announces Accounting Officer Resignation - TipRanks
HIMS: Leadership Change as Chief Accounting Officer Steps Down - GuruFocus
Hims & Hers Health Chief Accounting Officer to Step Down - Moomoo
Hims & Hers Health: CFO Yemi Okupe Will Assume Responsibilities of CAO During Search for Permanent CAO >HIMS - Moomoo
0.15%
0.52%
자본화:
|
볼륨(24시간):